Keyphrases
Older People
100%
Serum Phosphate
33%
Early-onset Dementia
33%
Vitamin K Status
33%
Critical Limb Ischemia
33%
Nutritional Supplementation
33%
Medical Management
33%
Orthostatic Hypotension
33%
Disease Prevalence
33%
Vascular Function
33%
Phosphate
26%
Oral nutritional Supplements
22%
Flavor Enhancement
22%
Sip Feeds
22%
Hypophosphataemia
13%
Hyperphosphataemia
13%
Phosphate Levels
13%
Malnutrition
11%
Randomized Controlled Trial
11%
Discharge from Hospital
11%
Adverse Outcomes
11%
Cardiovascular Risk
11%
Institutionalized Older People
11%
Dietary Fortification
11%
Educational Program
11%
Institutional Care
11%
Community-dwelling Older People
11%
Peripheral Arterial Disease
11%
Meal Environment
11%
Number of Participants
11%
Causes of Dementia
11%
Vitamin D Status
11%
Matrix Gla Protein
11%
Warfarin
9%
Remodeling Pattern
8%
Carotid Compliance
7%
Carotid Intima-media Thickness (cIMT)
7%
Vitamin K1
7%
Augmentation Index
7%
Flow-mediated Dilation
7%
Adverse Effects
6%
Phosphorus Deficiency
6%
Mild Cases
6%
Physiological Function
6%
HyPer
6%
Human Body
6%
Ischemic Pain
5%
Hypertension Management
5%
Iloprost
5%
Arterial Occlusion
5%
Medicine and Dentistry
Cardiovascular Risk
38%
Cardiovascular System
38%
Critical Limb Ischemia
33%
Hyperphosphatemia
33%
Hypophosphatemia
33%
Orthostatic Hypotension
33%
Magnetic Resonance Imaging
33%
Heart Ventricle Remodeling
33%
Cardiovascular Disease
31%
Cardiac Magnetic Resonance Imaging
20%
Adverse Event
16%
Phosphorus Deficiency
16%
Limb
14%
Blood Pressure
13%
Hazard Ratio
13%
Vitamin D
10%
Matrix Gla Protein
10%
Randomized Controlled Trial
9%
Arteriosclerosis Obliterans
9%
Warfarin
8%
Pulse Wave Velocity
6%
Flow Mediated Dilatation
6%
Intima-Media Thickness
6%
Phylloquinone
6%
Body Surface
6%
Brain Natriuretic Peptide
6%
Prospective Study
6%
Electronic Health Record
6%
Volunteer
6%
Kaplan Meier Method
6%
Proportional Hazards Model
6%
Pharmacology, Toxicology and Pharmaceutical Science
Hypophosphatemia
33%
Hyperphosphatemia
33%
Critical Limb Ischemia
33%
Phosphate Deficiency
16%
Adverse Event
16%
Randomized Controlled Trial
9%
Peripheral Occlusive Artery Disease
9%